Yahoo Finance Tech·1 min read
Vivani Medical price target lowered to $3.50 from $4 at H.C. Wainwright
Vivani Medical's price target revised downward by H.C. Wainwright
H.C. Wainwright has lowered its price target for Vivani Medical from $4 to $3.50 while maintaining a Buy rating on the shares. This adjustment follows the company's recent 2025 results and is primarily due to an increased share count. The analyst highlighted that Vivani's NPM-139 is positioned to potentially offer efficacy comparable to Wegovy, requiring only once or twice yearly administration.
Key Takeaways
- 1.
H.C. Wainwright lowered Vivani Medical's price target from $4 to $3.50.
- 2.
Analyst Yi Chen maintains a Buy rating on Vivani Medical shares.
Get your personalized feed
Trace groups the biggest stories, videos, and discussions into one feed so you can stay current without scanning ten tabs.
Try Trace free